RBC Europe’s Kazia Therapeutics KZIA Stock Holding History

RBC Europe’s Portfolio KZIA Stock Details KZIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	-$362	–	899
2021 Q3	$362	Hold	1	–	–	﹤0.01%	1203
2021 Q2	$316	Hold	1	–	–	﹤0.01%	1199
2021 Q1	$397	Hold	1	–	–	﹤0.01%	1148
2020 Q4	$276	Hold	1	–	–	﹤0.01%	1127
2020 Q3	$216	Hold	1	–	–	﹤0.01%	1072
2020 Q2	$108	Hold	1	–	–	﹤0.01%	1042
2020 Q1	$93	Hold	1	–	–	﹤0.01%	1021
2019 Q4	$139	Hold	1	–	–	﹤0.01%	1027
2019 Q3	$120	Hold	1	–	–	﹤0.01%	1031
2019 Q2	$83	Hold	1	–	–	﹤0.01%	1047
2019 Q1	$107	Hold	1	–	–	﹤0.01%	1059
2018 Q4	$78	Hold	1	–	–	﹤0.01%	1074
2018 Q3	$102	Hold	1	–	–	﹤0.01%	1110
2018 Q2	$95	Hold	1	–	–	﹤0.01%	1123
2018 Q1	$180	Buy	+1	New	+$231	﹤0.01%	1096

Other funds holding KZIA

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

RBC Europe's KZIA Position: Q4 2021 in Review

RBC Europe sold out of Kazia Therapeutics (KZIA) in Q4 2021, closing a stake of 1 share — an estimated $362 sold.

RBC Europe first reported a position in KZIA in Q1 2018 and held it in 15 quarters. The position peaked at $397 in Q1 2021. 10 funds tracked by Wall St. Rank hold KZIA as of Q4 2021.

RBC Europe reported no remaining Kazia Therapeutics position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 1 Kazia Therapeutics share in Q4 2021, an estimated $362.
RBC Europe first reported a position in Kazia Therapeutics in Q1 2018 and held it in 15 quarters.
RBC Europe's Kazia Therapeutics position peaked at $397 in Q1 2021.
10 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.